- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03253757
PrEP Impact Trial: A Pragmatic Health Technology Assessment of PrEP and Implementation
HIV pre-exposure prophylaxis (PrEP) is the use of anti-HIV medicines by HIV negative people in order to prevent them from becoming HIV positive if exposed to HIV.
Currently, the combination drug containing tenofovir and emtricitabine is licensed in Europe for use as HIV PrEP. We know from previous studies worldwide that this combination drug is very good at reducing the risk of HIV infection and several countries have implemented PrEP programmes to provide PrEP to individuals at high risk of HIV.
However, it is difficult to effectively plan for a national PrEP programme in England without knowing how many people will need PrEP, how many will want to take PrEP, and how long they will stay on PrEP.
In order to find this out, the PrEP Impact Trial will make PrEP available to at least 10,000 people over three years. HIV negative men and women attending sexual health clinics in England will have their risk of HIV assessed by their care team and be offered PrEP if they meet the eligibility criteria. Through the trial we will be able to measure how many attendees at sexual health clinics meet eligibility criteria for PrEP, how many of these take up the offer of PrEP and how long they remain on PrEP for.
There will not be any additional tests other than those recommended for the safe delivery of PrEP. These include tests for sexually transmitted infections (STIs) and HIV as well as urine and blood tests to monitor kidney function. Information about attendances and test results will be anonymously collected through the existing data reporting system that sexual health clinics currently use to report to Public Health England.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Förväntat)
Kontakter och platser
Studiekontakt
- Namn: Hannah Reaney
- Telefonnummer: 07887476175
- E-post: impact@ststcr.com
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
The participant populations for this trial will be men and women attending GUM clinics who belong to one of three populations recognised to be at high risk for HIV, namely:
A. Men (cisgender and transgender) and transgender women who:
- Have sex with men
- Have had an HIV negative test during an earlier episode of care in the preceding year
- Report condomless intercourse in the previous 3 months
- Affirm their likelihood of having condomless intercourse in the next 3 months
B. HIV negative partners of an HIV positive person when:
- The HIV positive partner is not known to be virally suppressed (<200 copies/ml for 6 months or more)
- Condomless intercourse is anticipated before treatment of the HIV positive partner takes effect
C.HIV negative persons who:
1. Are clinically assessed and considered to be at similar high risk of HIV acquisition as those with a serodiscordant partner who is not known to be virally suppressed
Beskrivning
Inclusion Criteria:
The participant populations for this trial will be men and women attending GUM clinics who belong to one of three populations recognised to be at high risk for HIV, namely:
A. Men (cisgender and transgender) and transgender women who:
- Have sex with men
- Have had an HIV negative test during an earlier episode of care in the preceding year
- Report condomless intercourse in the previous 3 months
- Affirm their likelihood of having condomless intercourse in the next 3 months
B. HIV negative partners of an HIV positive person when:
- The HIV positive partner is not known to be virally suppressed (<200 copies/ml for 6 months or more)
- Condomless intercourse is anticipated before treatment of the HIV positive partner takes effect
C.HIV negative persons who:
1. Are clinically assessed and considered to be at similar high risk of HIV acquisition as those with a serodiscordant partner who is not known to be virally suppressed
Participants will therefore be considered eligible for trial enrolment if they fulfil all the following individual eligibility criteria:
- Belongs to one of the three at high HIV risk populations described above
- Aged 16 years or over (no upper limit)
- Considered to be HIV negative on the day of enrolment
- Willing and able to provide informed consent
- Willing to adhere to the recommended PrEP regimen
- Willing to re-attend the trial clinic at appropriate intervals for risk assessment
Exclusion Criteria:
- An acute viral illness that could be due to HIV seroconversion
- Any contraindication to Tenofovir Disoproxil (TD)/ Emtricitabine (FTC)-
Studieplan
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
PrEP Eligibility
Tidsram: 3 years
|
The proportion of GUM clinic attendees meeting the eligibility criteria for PrEP
|
3 years
|
PrEP Eligibility (duration)
Tidsram: 3 years
|
The duration for which GUM clinic attendees are eligible for PreP
|
3 years
|
PrEP Uptake
Tidsram: 3 years
|
The proportion of PrEP eligible GUM clinic attendees prescribed PrEP
|
3 years
|
PrEP Uptake (duration)
Tidsram: 3 years
|
The duration for which eligible GUM clinic attendees use PrEP
|
3 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
HIV
Tidsram: 3 years
|
HIV diagnoses reported by sites and identified through the national surveillance dataset
|
3 years
|
STIs
Tidsram: 3 years
|
STI diagnoses (gonorrhoea, chlamydia, syphilis and hepatitis C) reported in the national surveillance dataset
|
3 years
|
Adverse Events
Tidsram: 3 years
|
|
3 years
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Förväntat)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- SSCR104
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på HIV-infektioner
-
Institut PasteurRekrytering
-
Duke UniversityAvslutadCentral Line-associated Bloodstream Infection (CLABSI)Förenta staterna
-
Catholic University of the Sacred HeartAvslutadCentral Line-associated Bloodstream Infection (CLABSI)
-
The University of Texas Health Science Center,...EurofinsAvslutadOdontogen Deep Space Neck InfectionFörenta staterna
-
Princess Maxima Center for Pediatric OncologyUMC Utrecht; Dutch Cancer SocietyRekryteringCentral Line-associated Bloodstream Infection (CLABSI)Nederländerna
-
University of MalayaTeleflexRekryteringCLABSI - Central Line Associated Bloodstream InfectionMalaysia
-
Johns Hopkins UniversityAvslutadCLABSI - Central Line Associated Bloodstream InfectionFörenta staterna
-
National Taiwan University Hospital Hsin-Chu BranchAvslutadCentral Line-associated Bloodstream Infection (CLABSI)
-
National Taiwan University HospitalAvslutadCentral Line-associated Bloodstream Infection (CLABSI)Taiwan
-
Boston Children's HospitalSterileCare Inc.Anmälan via inbjudanCentral Line komplikation | Central Line-associated Bloodstream Infection (CLABSI)Förenta staterna
Kliniska prövningar på This study is non-interventional.
-
AstraZenecaAvslutadBröstcancer | Onkologi | EpidemiologiAlgeriet
-
ER/LA Opioid REMS Program Companies (RPC)OkändDrogmissbruk | Opiatberoende | Opioidrelaterade störningar | Narkotikamissbruk